Table 2.
Summary of emerging TME-responsive nanomedicines for PDT-driven cancer immunotherapy. (↑= upregulation, ↓= downregulation).
| Formulation | Therapeutic agents | Stimuli | Immunologic modulation | Ref |
|---|---|---|---|---|
| PDPA-PPa micelles | PPa, SiRNA | pH | TAAs, mDC, HSP70, CD8+, NF-κB↑ PD-L1↓ | 86 |
| pRNVs/HPPH/IND nanovesicles | HPPH, pRNVs, IND | pH | TAAs, DC, mTOR, CD8+ ↑ Treg↓ | 36 |
| porphyrin-phospholipid liposomes | PPa, NLG-8189 | GSH | TAAs, mDC, CD8+, INF-γ, Trp↑ Kyn↓ | 82 |
| supramolecular nanocomplexes | PPa, NLG919 | GSH | TAAs, mDC, CD8+, Trp↑ Treg, Kyn↓ | 93 |
| biodegradable inorganic NPs | Ce6, CpG | GSH | TAAs, mDC, CD8+↑ | 96 |
| NP-sfb/Ce6 NPs | Ce6, sorafenib | ROS | TAAs, mDC, CD8+↑ MDSCs↓ | 83 |
| Ce6-doped mesoporous silica NPs | Ce6, CpG | Hypoxia | TAAs, mDC, CD4+, CD8+↑ | 84 |
| hypoxia-activatable polymeric micelles | DOX, ICG, CpG, αCTLA4 | Hypoxia | TAAs, mDC, CD4+, CD8+ TNF-α, IFN-γ, IL-12p70↑ | 104 |
| Boolean logic prodrug NPs | PPa, NLG919 | pH/GSH/MMP-2 | TAAs, mDC, CTLs, Trp↑ Treg, Kyn↓ | 108 |